Nitroglycerin
Nitro-dur, Nitrolingual Pumpspray, Nitromist, Nitrostat, Rectiv (nitroglycerin) is a small molecule pharmaceutical. Nitroglycerin was first approved as Nitroglycerin on 1982-01-01. It is used to treat angina pectoris, diffuse esophageal spasm, eclampsia, fissure in ano, and heart failure amongst others in the USA.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
digestive system diseases | D004066 |
respiratory tract diseases | D012140 |
urogenital diseases | D000091642 |
cardiovascular diseases | D002318 |
signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Nitro-dur, Nitrolingual pumpspray, Nitromist, Nitrostat, Rectiv (generic drugs available since 1988-05-24, discontinued: Gonitro, Minitran, Nitro, Nitro-bid, Nitrol, Nitrolingual, Nitronal, Transderm-nitro, Tridil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nitroglycerin
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RECTIV | AbbVie | N-021359 RX | 2011-06-21 | 1 products, RLD, RS |
NITROGLYCERIN IN DEXTROSE 5% | Baxter | N-019970 RX | 1989-12-29 | 3 products, RLD, RS |
NITROMIST | Evus Health Solutions | N-021780 RX | 2006-11-02 | 1 products, RLD, RS |
NITROLINGUAL PUMPSPRAY | Pohl-Boskamp | N-018705 RX | 1997-01-10 | 1 products, RLD, RS |
NITRO-DUR | USpharma | N-020145 RX | 1995-04-04 | 6 products, RLD, RS |
NITROSTAT | Viatris | N-021134 RX | 2000-05-01 | 3 products, RLD, RS |
Show 10 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
gonitro | New Drug Application | 2019-07-01 |
minitran | Export only | 2023-01-25 |
nitro-bid | ANDA | 2020-04-11 |
nitro-dur | New Drug Application | 2019-12-17 |
nitroglycerin | ANDA | 2023-06-05 |
nitrolingual | New Drug Application | 2019-07-01 |
nitromist | New Drug Application | 2020-06-08 |
nitrostat | New Drug Application | 2023-02-23 |
rectiv | New Drug Application | 2016-11-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
angina pectoris | EFO_0003913 | D000787 | I20 |
diffuse esophageal spasm | EFO_1001785 | D015155 | K22.4 |
eclampsia | HP_0100601 | D004461 | O15 |
fissure in ano | HP_0012390 | D005401 | K60.2 |
heart failure | EFO_0003144 | D006333 | I50 |
intraoperative complications | — | D007431 | — |
myocardial infarction | EFO_0000612 | D009203 | I21 |
pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
Agency Specific
FDA
EMA
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
206 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 2 | — | 1 | 1 | 2 | 6 |
Fissure in ano | D005401 | HP_0012390 | K60.2 | — | — | 1 | 2 | 2 | 5 |
Coronary artery disease | D003324 | I25.1 | 1 | 1 | — | 3 | — | 5 | |
Coronary disease | D003327 | — | — | 1 | 3 | — | 4 | ||
Stable angina | D060050 | I20.8 | — | — | — | 4 | — | 4 | |
Chronic renal insufficiency | D051436 | N18 | 1 | 1 | — | 1 | 1 | 3 | |
Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 1 | 2 | 3 |
Heart failure | D006333 | EFO_0003144 | I50 | — | 2 | 1 | 1 | — | 3 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | 1 | 1 | 3 |
Retained placenta | D018457 | O72.0 | — | — | — | 2 | — | 2 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | C85.9 | — | 4 | 4 | — | — | 8 | |
Raynaud disease | D011928 | EFO_1001145 | I73.0 | 2 | 2 | 5 | — | — | 8 |
Pain | D010146 | EFO_0003843 | R52 | — | 1 | 4 | — | 2 | 6 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | 1 | — | 1 | 3 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | — | 1 | 3 |
Vasodilation | D014664 | — | — | 1 | — | 2 | 3 | ||
Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | 1 | 3 | — | — | 3 |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | 2 | — | — | 2 |
Cardiac catheterization | D006328 | — | 1 | 2 | — | — | 2 | ||
Neonatal sepsis | D000071074 | HP_0040187 | — | — | 1 | — | — | 1 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 3 | 1 | — | — | 6 | 9 | ||
Mycosis fungoides | D009182 | C84.0 | — | 5 | — | — | 2 | 7 | |
T-cell lymphoma cutaneous | D016410 | C84.A | — | 2 | — | — | 1 | 3 | |
Non-hodgkin lymphoma | D008228 | C85.9 | 1 | 2 | — | — | 1 | 3 | |
Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 2 | 1 | — | — | — | 3 |
Non-small-cell lung carcinoma | D002289 | — | 2 | — | — | — | 2 | ||
Cerebral hemorrhage | D002543 | — | 1 | — | — | 1 | 2 | ||
Hodgkin disease | D006689 | C81 | — | 2 | — | — | — | 2 | |
Chest pain | D002637 | HP_0100749 | R07.9 | — | 1 | — | — | 1 | 2 |
Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | 1 | — | — | 1 | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
Inflammation | D007249 | 1 | — | — | — | — | 1 | ||
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
Peripheral arterial disease | D058729 | EFO_0004265 | 1 | — | — | — | — | 1 | |
Rectal neoplasms | D012004 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 5 | 5 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 2 | 2 |
Controlled hypotension | D007023 | — | — | — | — | 2 | 2 | ||
Vascular access devices | D062666 | — | — | — | — | 2 | 2 | ||
Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | — | 2 | 2 |
Pregnancy complications | D011248 | — | — | — | — | 2 | 2 | ||
Breech presentation | D001946 | HP_0001623 | — | — | — | — | 2 | 2 | |
Ischemia | D007511 | EFO_0000556 | — | — | — | — | 2 | 2 | |
Glucose metabolism disorders | D044882 | — | — | — | — | 1 | 1 |
Show 33 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | NITROGLYCERIN |
INN | — |
Description | Nitroglycerin is a nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain. It has a role as a vasodilator agent, a nitric oxide donor, an explosive, a prodrug, a tocolytic agent, a muscle relaxant and a xenobiotic. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-] |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
---|---|---|---|---|
VCV000018390 | ALDH2, 1510G>A, Glu504Lys | drug response | 2021-03-24 | 2B |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,126 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nitro-dur
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
16,902 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more